Blocking CXCR7-mediated adipose tissue macrophages chemotaxis attenuates insulin resistance and inflammation in obesity

Biochemical and Biophysical Research Communications

Volumn 479, Issue 4, 2016, Pages 649-655

  Peng, Hongxia ^a   Zhang, Hu ^a   Zhu, Honglei ^b  

^a FIRST PEOPLE S HOSPITAL OF SHANGQIU   (China)

^b Health Center of Chengguan Town   (China)

Author keywords

Chemotaxis; CXCR7; Inflammation; Insulin resistance; Obesity

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CXCL11 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; CHEMOKINE RECEPTOR CXCR; CMKOR1 PROTEIN, MOUSE; CXCL11 PROTEIN, MOUSE; CXCL12 PROTEIN, MOUSE; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE; STROMAL CELL DERIVED FACTOR 1;

ADIPOSE TISSUE; ADIPOSE TISSUE MACROPHAGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; MACROPHAGE MIGRATION INHIBITION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CHEMOTAXIS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM;

ADIPOSE TISSUE; ANIMALS; CHEMOKINE CXCL11; CHEMOKINE CXCL12; CHEMOTAXIS; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; OBESITY; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CXCR; UP-REGULATION;

EID: 84991738677     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.09.158     Document Type: Article

References (18)

1. [1] Malik, V.S., Willett, W.C., Hu, F.B., Global obesity: trends, risk factors and policy implications. Nat. Rev. Endocrinol. 9 (2013), 13–27.
2. [2] Ouchi, N., Parker, J.L., Lugus, J.J., et al. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11 (2011), 85–97.
3. [3] Weisberg, S.P., McCann, D., Desai, M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 112 (2003), 1796–1808.
4. [4] Kanda, H., Tateya, S., Tamori, Y., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig. 116 (2006), 1494–1505.
5. [5] Kitade, H., Sawamoto, K., Nagashimada, M., et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 61 (2012), 1680–1690.
6. [6] Chavey, C., Lazennec, G., Lagarrigue, S., et al. CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab. 9 (2009), 339–349.
7. [7] Tourniaire, F., Romier-Crouzet, B., Lee, J.H., et al. Chemokine expression in inflamed adipose tissue is mainly mediated by NF-kappaB. PLoS One, 8, 2013, e66515.
8. [8] Amisten, S., Neville, M., Hawkes, R., et al. An atlas of G-protein coupled receptor expression and function in human subcutaneous adipose tissue. Pharmacol. Ther. 146 (2015), 61–93.
9. [9] Ma, W., Liu, Y., Wang, C., et al. Atorvastatin inhibits CXCR7 induction to reduce macrophage migration. Biochem. Pharmacol. 89 (2014), 99–108.
10. [10] Thelen, M., Thelen, S., CXCR7, CXCR4 and CXCL12: an eccentric trio?. J. Neuroimmunol. 198 (2008), 9–13.
11. [11] Odemis, V., Lipfert, J., Kraft, R., et al. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells. Glia 60 (2012), 372–381.
12. [12] Costantini, S., Raucci, R., De Vero, T., et al. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach. Cytokine 64 (2013), 316–321.
13. [13] Bao, J., Zhu, J., Luo, S., et al. CXCR7 suppression modulates microglial chemotaxis to ameliorate experimentally-induced autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 469 (2016), 1–7.
14. [14] Zhao, D., Zhu, Z., Li, D., et al. Pioglitazone suppresses CXCR7 expression to inhibit human macrophage chemotaxis through peroxisome proliferator-activated receptor gamma. Biochemistry 54 (2015), 6806–6814.
15. [15] Suganami, T., Nishida, J., Ogawa, Y., A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 2062–2068.
16. [16] Ota, T., Chemokine systems link obesity to insulin resistance. Diabetes Metab. J. 37 (2013), 165–172.
17. [17] Dominguez, H., Storgaard, H., Rask-Madsen, C., et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42 (2005), 517–525.
18. [18] Larsen, C.M., Faulenbach, M., Vaag, A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 (2007), 1517–1526.